Compare PRAX & EMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | EMN |
|---|---|---|
| Founded | 2015 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.0B |
| IPO Year | 2020 | 1996 |
| Metric | PRAX | EMN |
|---|---|---|
| Price | $331.79 | $73.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $572.13 | $78.62 |
| AVG Volume (30 Days) | 345.8K | ★ 1.4M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.10 |
| Revenue | N/A | ★ $8,752,000,000.00 |
| Revenue This Year | N/A | $1.98 |
| Revenue Next Year | $6,395.88 | $3.39 |
| P/E Ratio | ★ N/A | $18.11 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.79 | $56.11 |
| 52 Week High | $354.87 | $83.47 |
| Indicator | PRAX | EMN |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 51.50 |
| Support Level | $282.49 | $65.96 |
| Resistance Level | $327.65 | $82.13 |
| Average True Range (ATR) | 17.60 | 2.38 |
| MACD | 2.86 | 0.24 |
| Stochastic Oscillator | 81.68 | 58.02 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.